<SEC-DOCUMENT>0001193125-19-003188.txt : 20190107
<SEC-HEADER>0001193125-19-003188.hdr.sgml : 20190107
<ACCEPTANCE-DATETIME>20190107080037
ACCESSION NUMBER:		0001193125-19-003188
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190107
DATE AS OF CHANGE:		20190107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareDx, Inc.
		CENTRAL INDEX KEY:			0001217234
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				943316839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36536
		FILM NUMBER:		19512206

	BUSINESS ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-287-2300

	MAIL ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XDx, Inc.
		DATE OF NAME CHANGE:	20071010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXPRESSION DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20030203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d687416d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;7, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CAREDX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36536</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-3316839</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3260 Bayshore Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Brisbane, California 94005 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">287-2300</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name, or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp; &#9746;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;7, 2019, CareDx, Inc. (the &#147;Company&#148;) issued a press release announcing certain preliminary financial results for the quarter and
year ended December&nbsp;31, 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preliminary financial information presented in the press release is based on the Company&#146;s current expectations and may be adjusted as a result of, among other things, completion of the audit of the Company&#146;s financial statements as of,
and for the year ended, December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is
intended to be furnished under Item 2.02 and Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cautionary Note Regarding Forward-Looking Statements</I>. This Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and the press release furnished as Exhibit 99.1 hereto contain forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or
implied by these statements. Please refer to the note in the press release under the heading &#147;Forward-Looking Statements&#148; regarding these forward-looking statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are being furnished
herewith: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d687416dex991.htm">Press Release, dated January&nbsp;7, 2019 regarding preliminary financial results of CareDx, Inc. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;7, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CAREDX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Bell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d687416dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g687416g43g21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BRISBANE, Calif., January&nbsp;7, 2019 (GLOBE NEWSWIRE) &#151;&nbsp;CareDx, Inc.&nbsp;(NASDAQ: CDNA), a molecular diagnostics company focused on the
discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the fourth quarter and full year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter Highlights: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued acceleration of AlloSure penetration </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the fourth quarter of 2018, 100 U.S. transplant centers provided AlloSure testing to 3,377 patients
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued progress in AlloSure Registry <FONT STYLE="white-space:nowrap">(K-OAR)</FONT> enrollment, with 47
centers initiated and 748 patients enrolled as of December&nbsp;31, 2018 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Achieved preliminary fourth quarter total revenue of between $23.2&nbsp;million and $23.5&nbsp;million
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Testing services revenue expected to be between $18.5&nbsp;million and $18.8&nbsp;million, with 4,575 AlloSure
and 4,057 AlloMap patient results provided </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product revenue expected to be approximately $4.6&nbsp;million </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthened balance sheet through public equity offering and repayment of outstanding debt
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary cash and cash equivalents of $64.6&nbsp;million at December&nbsp;31, 2018 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2018 was a breakout year for CareDx. We saw rapid adoption of AlloSure in transplant centers across the U.S., resulting in strong revenue growth. We
also delivered on our goal of achieving positive adjusted EBITDA ahead of schedule in the third quarter, and significantly strengthened both our financial position and executive leadership team,&#148; said Peter Maag, CareDx Chief Executive Officer.
&#147;We are now firmly positioned as the leading provider of genomics-based information in transplantation, and believe that we have the momentum and capabilities to drive continued innovation and growth in 2019.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Full Year and Fourth Quarter 2018 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial results for the three months and year ended December&nbsp;31, 2018 are preliminary and subject to completion of the audit of the Company&#146;s
consolidated financial statements as of, and for the year ended, December&nbsp;31, 2018, and will be updated with the filing of the upcoming annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue for the three months ended December&nbsp;31, 2018 is expected to be between $23.2&nbsp;million and $23.5&nbsp;million, an increase of 85%
to 88% compared with $12.5&nbsp;million in the fourth quarter of 2017.&nbsp;Testing revenue for the quarter is expected to be between $18.5&nbsp;million to $18.8&nbsp;million, compared with $8.6&nbsp;million in the same period in 2017. Product
revenue in the three months ended December&nbsp;31, 2018 is expected to be $4.6&nbsp;million, compared to $3.7&nbsp;million in the same period in 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue for the full year ended December&nbsp;31, 2018 is expected to be between $76.2&nbsp;million and $76.5&nbsp;million, an increase of approximately 58%
compared with $48.3&nbsp;million in 2017.&nbsp;Testing revenue for the year ended December&nbsp;31, 2018 is expected to be between $59.9&nbsp;million to $60.2&nbsp;million, compared with $33.1&nbsp;million in 2017. Product revenue for the full year
2018 is expected to be $15.7&nbsp;million, compared to $14.6&nbsp;million in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary cash and cash equivalents were $64.6&nbsp;million as of
December&nbsp;31, 2018. In the fourth quarter of 2018, CareDx received $53.8&nbsp;million net cash from a public offering of common stock and exercises of common stock warrants and options, and used $16.7&nbsp;million cash to repay all outstanding
debt. CareDx expects to report positive cash flow from operating activities in the three months ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx will report fourth
quarter and full year 2018 financial results and provide 2019 financial guidance on its March 2019 earnings call. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;CareDx </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of
clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the <FONT STYLE="white-space:nowrap">pre-</FONT> and post-transplant testing continuum, and is the leading provider of genomics-based
information for transplant patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit: www.CareDx.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes
forward-looking statements, including expectations regarding the Company&#146;s financial results, including expectations regarding the Company&#146;s fourth quarter and full-year fiscal 2018 revenue, testing revenue and product revenue, 2018 <FONT
STYLE="white-space:nowrap">year-end</FONT> cash and cash equivalents, and the Company&#146;s prospects, including prospects for continued innovation and growth in 2019. These forward-looking statements are based upon information that is currently
available </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including completion of the audit of the Company&#146;s consolidated
financial statements as of, and for the year ended, December&nbsp;31, 2018, general economic and market factors, among others&nbsp;discussed in CareDx&#146;s filings with the SEC, including the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 filed by CareDx with the SEC on March&nbsp;22, 2018 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause
CareDx&#146;s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx&#146;s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or
undertaking to update or revise any such forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Clair </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Integrated Corporate Relations, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-277-1266</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">david.clair@icrinc.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g687416g43g21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g687416g43g21.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MHJ48)2W.#&3ISK.5+X?N-NM3D"@ H * "@ H * "@ H * "@ H * "@ H *
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M56;&%( (P2.N: ,'X3V/B+Q[H]YJ6J>-=<A6"?R4CMK@+GY0222#ZT >B/\
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M3]3M8[FUE7YHW&1['V(]: /F/X)>&[#7_&]_::BC364%LS- 6(64AU # ?>
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MV?[1;VUB56RAN;J. ;]PP%<#DGF@#Z>EXA?_ '30!\V_L\,#X^UC!'-HV/\
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M65R%*^;#=!6P>H^[TH ] TVR;3M/BM&N[B[,8(\ZX8-(W.>2 /ITH Y/Q?\
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MKATBAB9K>:6%@Q)7RV"G(QWSF@#3U2XN8K.R3S1 ]Q,D4LJ?P YSC/KC'XT
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MZ4 10:/8V]Y)=K;H9V8,&*C*84+A>.!@4 /;2M/9XW:R@+1 !"4&5 .1CZ4
M2&QM638;:,IM9,;1C:W+#Z&@!S6=LUI]E:!&M]NWRRN5QZ8H @;1]-:&.%K"
MW,<>2JF,8&>M $CV%G);M ]M$T3'<4*C!/K^E $T4,<$2Q0QK'&HPJJ, 4 /
$H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
